These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21154165)

  • 1. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Curr Opin Mol Ther; 2010 Dec; 12(6):734-40. PubMed ID: 21154165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.
    Easdale S; Stasi R
    Expert Opin Biol Ther; 2013 Jul; 13(7):1085-92. PubMed ID: 23688321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced opsonisation of Rhesus D-positive human red blood cells by recombinant polymeric immunoglobulin G anti-G antibodies.
    Díaz-Solano D; Fuenmayor J; Montaño RF
    Blood Transfus; 2018 Feb; 16(2):200-208. PubMed ID: 28686149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
    Brinc D; Lazarus AH
    Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo studies of monoclonal anti-D and the mechanism of immune suppression.
    Kumpel BM
    Transfus Clin Biol; 2002 Jan; 9(1):9-14. PubMed ID: 11889904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The introduction of human monoclonal anti-D for therapeutic use.
    Fletcher A; Thomson A
    Transfus Med Rev; 1995 Oct; 9(4):314-26. PubMed ID: 8541714
    [No Abstract]   [Full Text] [Related]  

  • 7. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists.
    Urbaniak SJ
    Transfusion; 1998 Jan; 38(1):97-9. PubMed ID: 9482402
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunological principle of development of red blood cell alloimmunization in pregnancy, hemolytic disease of the fetus and prevention of RhD alloimmunization in RhD negative women.
    Roubalová L; Lubušký M
    Ceska Gynekol; 2020; 85(6):408-416. PubMed ID: 33711901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic basis and immunoprophylaxis of RhD induced hemolytic disease of the newborn (HDN).
    Payam Khaja Pasha R; Shokri F
    Iran J Immunol; 2008 Dec; 5(4):189-200. PubMed ID: 19098362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal versus polyclonal anti-D in the treatment of ITP.
    Lazarus AH
    Expert Opin Biol Ther; 2013 Oct; 13(10):1353-6. PubMed ID: 23919777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn.
    Kumpel BM
    Transfus Clin Biol; 1997 Jul; 4(4):351-6. PubMed ID: 9269715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells.
    Nielsen LK; Norderhaug L; Sandlie I; Dziegiel MH
    APMIS; 2006 May; 114(5):345-51. PubMed ID: 16725010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal anti-D development programme.
    Kumpel BM
    Transpl Immunol; 2002 Aug; 10(2-3):199-204. PubMed ID: 12216950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
    Robak T; Windyga J; Trelinski J; von Depka Prondzinski M; Giagounidis A; Doyen C; Janssens A; Alvarez-Román MT; Jarque I; Loscertales J; Rus GP; Hellmann A; Jêdrzejczak WW; Kuliczkowski K; Golubovic LM; Celeketic D; Cucuianu A; Gheorghita E; Lazaroiu M; Shpilberg O; Attias D; Karyagina E; Svetlana K; Vilchevska K; Cooper N; Talks K; Prabhu M; Sripada P; Bharadwaj TP; Næsted H; Skartved NJ; Frandsen TP; Flensburg MF; Andersen PS; Petersen J
    Blood; 2012 Nov; 120(18):3670-6. PubMed ID: 22915649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
    Kumpel BM
    Clin Exp Immunol; 2008 Oct; 154(1):1-5. PubMed ID: 18727626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.
    Song S; Crow AR; Siragam V; Freedman J; Lazarus AH
    Blood; 2005 Feb; 105(4):1546-8. PubMed ID: 15479722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current viewpoints in the anti-D prevention of rhesus alloimmunization in the pregnant woman and of hemolytic disease of the newborn infant (a review of the literature)].
    Spasova K; Vŭlcheva B
    Akush Ginekol (Sofiia); 1986; 25(3):84-90. PubMed ID: 3019168
    [No Abstract]   [Full Text] [Related]  

  • 18. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
    Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
    Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse effects and patient information].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More on the R0 Har antigenic complex.
    Case J
    Transfusion; 1996; 36(11-12):1034-5. PubMed ID: 8937417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.